Invasive NSTEMI Strategy Shows No Benefit in Frail Patients
Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.
-
By
-
Kathryn Wighton
-
May 6, 2026
-
Clinical Scorecard: Invasive NSTEMI Strategy Shows No Benefit in Frail Patients
At a Glance
| Category | Detail |
|---|
| Condition | Non-ST-Elevation Myocardial Infarction (NSTEMI) in Frail Patients |
| Key Mechanisms | Comparison of invasive strategy versus conservative management in frail patients aged 75 and older. |
| Target Population | Patients aged 75 years or older with frailty and NSTEMI. |
| Care Setting | Cardiology, specifically in the context of acute coronary syndrome management. |
Key Highlights
- Invasive strategy did not reduce cardiovascular death or nonfatal myocardial infarction compared to conservative management.
- Higher frailty levels were associated with worse outcomes in invasive management.
- 38% of invasive care patients experienced primary outcome versus 29% in conservative care.
- Procedural complications were numerically more common in frail patients undergoing invasive treatment.
- Findings suggest frailty modifies the balance of benefit and risk with invasive strategies.
Guideline-Based Recommendations
Diagnosis
- Assess frailty using Fried frailty criteria in patients with NSTEMI.
Management
- Consider conservative management for frail patients with NSTEMI.
Monitoring & Follow-up
- Monitor for procedural complications in frail patients undergoing invasive procedures.
Risks
- Be aware of potential harm associated with invasive strategies in patients with higher frailty.
Patient & Prescribing Data
Frail patients aged 75 years or older with NSTEMI.
Invasive management may not provide expected benefits and could increase risks in frail patients.
Clinical Best Practices
- Evaluate frailty severity when making treatment decisions for older patients.
- Utilize conservative management strategies in frail patients with NSTEMI.
References
